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A Closer Look at the Psychiatric Effects of Deep Brain 
Stimulation to Further Guide Treatment of Refractory 
Epilepsy: A Focused Review
LaTangela R. Smith, DO
Psychiatric effects associated with each DBS target. Not all studies reported stimulation parameters. The parameters listed are a 
range of the parameters reported for each target. 
ANT – Anterior nucleus of thalamus, CB – cerebellum, CMN – centromedian nucleus, HIP – hippocampus, HyTH – hypothalamus, IC 
– internal capsule (anterior limb, VC/VC – ventral capsule/ventral striatum), NA – nucleus accumbens, SCG – subcallosal cingulate 
gyrus, STN/GPi – subthalamic nucleus/globus pallidus internus, VIM – ventral intermediate nucleus    
CCH – chronic cluster headache, OCD – obsessive compulsive disorder, TRD – treatment resistant depression, PD – Parkinson’s 
disease, ET – essential tremor, AT – axial tremor 
SI – suicidal ideation, SA – suicide attempt
RESULTSINTRODUCTION
The effective treatment of medically-refractory epilepsy 
continues to be a challenge in many patients. This is 
especially true in those patients who do not meet criteria for 
resective surgery. The advent of neurostimulation for the 
treatment of refractory epilepsy has certainly increased the 
probability of gaining better control in these patients. Until 
more recently, vagal nerve stimulation was the only FDA 
approved neuromodulating treatment for the management 
of refractory epilepsy. In 2013 responsive neurostimulation 
(RNS) emerged as a promising treatment. However, it was 
not without limitations including the number of seizure foci 
that could be targeted and the inability to obtain magnetic 
brain imaging following placement. In 2018 deep brain 
stimulation (DBS) was finally approved for the treatment of 
medically-refractory epilepsy, though the 
antiepileptogenesis of deep brain stimulation has been 
explored for decades1. The results of the SANTE (Stimulation 
of the Anterior Nucleus of the Thalamus for Epilepsy) trial 
led to this FDA approval and, though very promising given 
the efficacy in seizure reduction, concerns regarding the 
possible risk of adverse, psychiatric effects were raised2,3. 
The adverse, psychiatric effects reported in the SANTE trial 
may result in avoiding the use of DBS in epilepsy patients 
with history of depression, suicidality and other known 
psychiatric illness. While this is a reasonable caution, in 
many refractory epilepsy patients DBS may be the only 
option for improved seizure control. Thus, it is prudent to 
more thoroughly explore the possible, psychiatric risks 
associated with DBS. This review will focus on the psychiatric 
effects reported in various DBS targets to better determine 
the mental health risks and identify safer targets.  
METHODS
A search of the clinical literature published between January 1, 
1990 and December 31, 2019 was completed. The most 
relevant papers were reviewed with a focus on adverse effects, 
specifically adverse, psychiatric effects. The references cited in 
selected papers were utilized to obtain additional resources. 
DISCUSSION
By far, the DBS targets most associated with adverse, 
psychiatric effects include the STN and GPI as well as the SCG, IC 
and VIM. Mixed results were noted for the ANT as approximately 
half of the studies noted no adverse, psychiatric effects. For the 
SCG and IC, it is unclear how much the underlying, psychiatric 
illness of the patients contributed as for most of the studies 
involving these targets the indication for stimulation was 
treatment resistant depression. Stimulation of the SCG and IC has 
also shown improvement in depression4. 
The CB, CMN, HIP and HyTH are targets that may be deemed 
safer for further exploration. No adverse, psychiatric effects were 
reported and favorable effects were associated with targeting of 
the CB and HyTH. Hippocampal volume loss has been associated 
with depressive symptoms, thus hippocampal stimulation may 
lead to improvements in mood over time5. The involvement of 
the CMN and HyTH in mood is unclear. There is, however, some 
thought that the CB may have implications in modulating mood 
and psychiatric illness6.  
Though there are possible risks of adverse, psychiatric effects 
with select DBS targets, this may not have to completely 
preclude their use in patients with psychiatric illness. 
Understanding the risks and appropriately educating and 
counseling patients may reduce risks. The results of this review 
have re-demonstrated the psychiatric risks associated with STN 
stimulation. However, improvements in depression, anxiety and 
coping has been shown in STN DBS patients who received 
appropriate psychiatric education prior to and after 
implantation7.
The limitations of this review include the lack of consistency 
among studies in reporting adverse, psychiatric effects as well as 
small sample sizes. Additionally, few studies utilized standardized 
methods for collecting data on psychiatric symptoms. 
CONCLUSION
In conclusion the CB, CMN, HIP and HyTH are DBS targets not 
readily associated with adverse, psychiatric effects. These 
targets should be further explored to better determine their 
efficacy in the treatment of medically-refractory epilepsy. 
Additionally, more precise and standardized collection of 
psychiatric data in DBS epilepsy patients is needed. Pre-
implantation education and close post-implantation evaluation 
for psychiatric effects may decrease the overall risks of 
psychiatric morbidity and mortality. References listed in supplemental document
